Home › Glioblastoma › North Carolina › Durham
Glioblastoma clinical trials in Durham, NC
20 studies for Glioblastoma are looking for participants at sites in and around Durham (within about 30 miles). Open a study to see who can join and how to contact the study team.
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
RecruitingPhase 3
- University of North Carolina, Chapel Hill · 10 mi away
Targeted Pediatric High-Grade Glioma Therapy
RecruitingObservational study
- Duke University Health System, Durham
Study of Olutasidenib and Temozolomide in HGG
RecruitingPhase 2
- Duke University Health System, Durham
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
RecruitingPhase 3
- Duke Cancer Institute, Durham
Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial
RecruitingPhase 2
- Duke University Medical Center, Durham
BRiTE - Bispecific T Cell Engager for Patients With Glioblastoma
RecruitingPhase 1
- Duke University Medical Center, Durham
A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment
RecruitingPhase 2
- Duke University, Durham
A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial
RecruitingPhase 2
- Duke University, Durham
Lerapolturev (PVSRIPO) in GBM
RecruitingPhase 2
- Duke University Medical Center, Durham
DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
RecruitingPhase 2
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi away
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
RecruitingEarly phase 1Healthy volunteers welcome
- Duke University Health System, Durham
Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma
RecruitingPhase 1
- Duke University Medical Center, Durham
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RecruitingPhase 2
- Duke University Health System, Durham
Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc
RecruitingPhase 1
- Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi away
Key Longitudinal Associations With Risk and Glioblastoma Outcomes
RecruitingObservational study
- Duke University, Durham
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Chapel Hill · 10 mi away
D2C7-IT + 2141-V11 Combination Post-resection in rGBM
RecruitingPhase 1
- Duke University Medical Center, Durham
D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients
RecruitingPhase 1/2
- Duke University Medical Center, Durham
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
RecruitingPhase 2
- University of North Carolina, Chapel Hill · 10 mi away
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
RecruitingPhase 1
- Duke University, Durham
Glioblastoma trials in other cities
- New York City, NY30 studies
- Boston, MA29 studies
- Houston, TX25 studies
- Los Angeles, CA22 studies
- San Francisco, CA18 studies
- Chicago, IL16 studies
- Washington, DC15 studies
- Rochester, MN15 studies
- Columbus, OH14 studies
- Miami, FL14 studies
- Jacksonville, FL13 studies
- Aurora, CO12 studies
Other studies in Durham
- Breast Cancer63 studies
- Cancer (all types)59 studies
- Non-Small Cell Lung Cancer39 studies
- Multiple Myeloma37 studies
- Acute Myeloid Leukemia33 studies
- Metastatic Cancer33 studies
- Lung Cancer32 studies
- Prostate Cancer32 studies
- Colorectal Cancer28 studies
- Chronic Lymphocytic Leukemia27 studies
- Ovarian Cancer27 studies
- Heart Failure26 studies
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.